The South Korea’s aesthetic injectables market is witnessing a surge in traction, propelled by heightening consumer knowledge and ongoing technical innovations. Advances in product formulations and treatment approaches are also contributing to the market expansion. As a result, the market is forecast to grow at a compound annual growth rate (CAGR) of 7% through 2036, reveals GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Aesthetic Injectables Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that the growing use of injectables across cosmetic applications and the continued expansion of the medical aesthetics sector underpin South Korea’s aesthetic injectables market.

In line with this, Amorepacific Holdings’ investment in HIGHER Corporation in July 2026 marks a strategic move to strengthen its position in medical aesthetics. The collaboration brings together Amorepacific Holdings beauty capabilities and HIGHER’s medical aesthetics expertise and is expected to support the development and commercialization of aesthetic injectables and related technologies. Such investments help accelerate product rollout and market expansion by improving commercialization capabilities and broadening access through stronger go-to-market execution.

Anindita Ghosh, Medical Devices Analyst at GlobalData, comments: “South Korea is witnessing a broadening aesthetic injectables market, with injectables playing an important role in meeting the demand for non-surgical cosmetic interventions. Strong consumer uptake across hyaluronic acid (HA) fillers, poly-L-lactic acid (PLLA), and polymethyl methacrylate (PMMA) categories support this growth, alongside the ongoing product innovation and an expanding network of aesthetic clinics. At the same time, increasing emphasis on practitioner training, patient safety, and regulatory compliance will influence product adoption in the years ahead.”

At the product level, instead of developing a new filler that provides more facial volume, companies might develop products that improve skin hydration and elasticity and can be used in combination with a filler to achieve a more natural overall improvement in appearance. Innovation is increasingly focused on skin-quality outcomes. HIGHER Corporation’s HILO WAVE, a Dual-HA collagen booster, is one example of this shift, as manufacturers develop formulations to better match evolving patient expectations and clinic protocols.

South Korea’s aesthetic injectables industry is export-led, as domestic manufacturers expand international distribution and pursue growth beyond the home market.

Ghosh concludes: “Significant export opportunities and the enduring consumer desire to look younger will shape the next phase of the South Korean market. Rising investment will increasingly favor companies that can convert new formulations and skin-quality-focused innovations into widely adopted, regulator-ready offerings scaling beyond the domestic clinic network as competition intensifies.”